Status:
RECRUITING
Multicentre Study for Data Collection, Development, and Evaluation of Novel CRC Screening and Diagnostic Methods
Lead Sponsor:
Firalis SA
Collaborating Sponsors:
University Medical Center Mainz
Conditions:
Colorectal Cancer
Eligibility:
All Genders
18+ years
Brief Summary
The primary goal is to develop easy accessible diagnostic tools for high risk subjects for colon cancer in different European populations to improve early CRC detection. These CRC screening technologi...
Detailed Description
Colorectal Cancer (CRC) is the third most commonly occurring cancer in men and the second most commonly occurring cancer in women. CRC can often be prevented through regular screening. Although colono...
Eligibility Criteria
Inclusion
- CRC Group
- Signature of the informed consent indicating that the subject accepts to participate in the study and to comply with the requirements and restrictions inherent in this study.
- Subjects aged ≥18 years
- Subject is willing to undergo FOBT test, colonoscopy, and tissue biopsy
- Subject for whom the decision to perform a colonoscopy has been made by the treating physician
- Subject has positive CRC diagnosis according to colonoscopy result
- Covered by a Health Insurance System
- Subject is able to comply with all study procedures
- Control Group with risks and presence of polyps
- Signature of the informed consent indicating that the subject accepts to participate in the study and to comply with the requirements and restrictions inherent in this study.
- Subjects aged ≥18 years
- Otherwise healthy individuals with recognized risk factors for CRC development defined by either heredity and/or obesity and/or smoking and/or excess alcohol consumption and/or hyperlipidaemia.
- Subject be willing to undergo FOBT test, colonoscopy, and tissue biopsy
- Subject has negative CRC diagnosis according to colonoscopy result
- Covered by a Health Insurance System, which will cover colonoscopy as screening in patients with risk factors and alarm symptoms such as abdominal pain, change in stool texture, change in stool frequency, blood in stool/rectal bleeding, diarrhea, constipation, abdominal bloating, weight loss, tiredness.
- Control Group with risks and absence of polyps
- Signature of the informed consent indicating that the subject accepts to participate in the study and to comply with the requirements and restrictions inherent in this study.
- Subjects aged ≥18 years
- Otherwise healthy individuals with recognized risk factors for CRC development defined by either heredity and/or obesity and/or smoking and/or excess alcohol consumption and/or hyperlipidaemia.
- Subject be willing to undergo FOBT test, colonoscopy, and tissue biopsy
- Subject has negative CRC diagnosis according to colonoscopy result
- Covered by a Health Insurance System, which will cover colonoscopy as screening in patients with risk factors and alarm symptoms such as abdominal pain, change in stool texture, change in stool frequency, blood in stool/rectal bleeding, diarrhea, constipation, abdominal bloating, weight loss, tiredness.
- Control Group with no risks
- Signature of the informed consent indicating that the subject accepts to participate in the study and to comply with the requirements and restrictions inherent in this study.
- Subjects aged ≥40 years
- Otherwise healthy individuals without any recognized risk factors for CRC development defined by either heredity and/or obesity and/or smoking and/or excess alcohol consumption and/or hyperlipidemia.
- Subject be willing to undergo FOBT test
- Subject has negative FOBT result
Exclusion
- For the CRC Group
- Legal incapacity or limited legal capacity
- Subject did not sign the Informed Consent form
- Subject who, according to the investigator's assessment, presents with an unstable medical condition contraindicating the performance of the planned blood test, stool test or breath test
- Subject has had surgery in the previous 6-8 weeks or is under medication for CRC treatment.
- For the control groups
- Legal incapacity or limited legal capacity
- Subject did not sign the Informed Consent form
- Previous history of any type of cancer
- Gastrointestinal disorders or other serious acute or chronic diseases
Key Trial Info
Start Date :
August 1 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2026
Estimated Enrollment :
4100 Patients enrolled
Trial Details
Trial ID
NCT06515821
Start Date
August 1 2024
End Date
December 31 2026
Last Update
September 10 2025
Active Locations (8)
Enter a location and click search to find clinical trials sorted by distance.
1
Military Medical Academy Sofia, Gastroenterology Clinic, 3 Sveti Georgi Sofiiski str., Sofia 1606, Bulgaria
Sofia, Bulgaria, 1606
2
University Specialised Hospital for Active Treatment of Oncology Departement of Gastroenterology.
Sofia, Bulgaria, 1797
3
UFC: Université de Franche-Comté Oncology department CHU Besançon
Besançon, France, 25030
4
MKI UKSH Lübeck
Lübeck, Germany, 23538